Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Heparan sulfate proteoglycans as targets for cancer therapy: a review

Full text
Onyeisi, Jessica Oyie Sousa [1] ; Ferreira, Bianca Zaia Franco [2] ; Nader, Helena Bonciani [1] ; Lopes, Carla Cristina [2, 1]
Total Authors: 4
[1] Univ Fed Sao Paulo, Dept Bioquim, Disciplina Biol Mol, Sao Paulo, SP - Brazil
[2] Univ Fed Sao Paulo, Inst Ciencias Ambientais Quim & Farmaceut, Diadema, SP - Brazil
Total Affiliations: 2
Document type: Review article
Source: CANCER BIOLOGY & THERAPY; v. 21, n. 12 NOV 2020.
Web of Science Citations: 0

Heparan sulfate proteoglycans (HSPGs) play important roles in cancer initiation and progression, by interacting with the signaling pathways that affect proliferation, adhesion, invasion and angiogenesis. These roles suggest the possibility of various strategies of regulation of these molecules. In this review, we demonstrated that the anticancer drugs can regulate the heparan sulfate proteoglycans activity in different ways: some act directly in core protein, and can bind to a specific type of HSPG. Others drugs interact with glycosaminoglycans chains, and others can act directly in enzymes that regulate HSPGs levels. We also demonstrated that the HSPGs drug targets can be divided into four groups: monoclonal antibodies, antitumor antibiotic, natural products, and mimetics peptide. Interestingly, many drugs demonstrated in this review are approved by FDA and is used in cancer therapy (Food and Drug Administration) like trastuzumab, panitumumab, bleomycin and bisphosphonate zoledronic acid (ASCO) or are in clinical trials like codrituzumab and genistein. This review should help researchers to understand the mechanism of action of anticancer drugs existing and also may inspire the discovery of new drugs that regulate the heparan sulfate proteoglycans activity. (AU)

FAPESP's process: 19/19739-2 - Role of syndecan-4 in extracellular matrix remodeling in anoikis-resistant endothelial cells
Grantee:Carla Cristina Lopes de Azevedo
Support type: Regular Research Grants